Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O14979

UPID:
HNRDL_HUMAN

ALTERNATIVE NAMES:
AU-rich element RNA-binding factor; JKT41-binding protein; Protein laAUF1

ALTERNATIVE UPACC:
O14979; Q6SPF2; Q7KZ74; Q7KZ75; Q96IM0; Q96S43

BACKGROUND:
The Heterogeneous nuclear ribonucleoprotein D-like, with alternative names such as AU-rich element RNA-binding factor, is pivotal in transcriptional dynamics, engaging in both suppression and activation. Its binding affinity to RNA molecules, especially those with AU-rich elements, underscores its regulatory significance in gene expression, impacting a wide array of biological processes including muscle differentiation.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the pathogenesis of Muscular dystrophy, limb-girdle, autosomal dominant 3, a deeper understanding of Heterogeneous nuclear ribonucleoprotein D-like offers promising avenues for the development of novel therapeutic interventions for muscular dystrophies and potentially other related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.